For comments, suggestions
Created with Raphaël 2.1.0 27.04.2018 Filing date 25.11.2019 Validation fee payment 30.04.2020 (A1) Patent application published 29.05.2023 AGEPI application filing date 31.08.2023 (T2) Translation of the validated European patent 26.04.2025 27.04.2026 Valid until 28.04.2027 Renewal fee to be paid until 27.04.2038 Patent will expire on

Patent in force


(210)Number of the EPO application18720255
(220)Filing date of the EPO application2018.04.27
(80)EPO patent specification publication (B)EPB nr. 12/2023, 2023.03.22
(110)EPO patent number3615544
(11)Number of the documentMD 3615544 T2
(21)Number of the applicatione 2020 0225
(71)Name(s) of applicant(s), code of the countryPharma Mar S.A., ES;
(72)Name(s) of inventor(s), code of the countryCUEVAS MARCHANTE Maria del Carmen, ES;
FRANCESCH SOLLOSO Andres, ES;
MARTINEZ BARRASA Valentin, ES;
(73)Name(s) of owner(s), code of the countryPharma Mar S.A., ES;
(54)Title of the inventionAntitumoral compounds
(13)Kind-of-document code T2
(51)International Patent Classification C07D 515/22 (2006.01.01); A61P 35/00 (2006.01.01); A61K 31/4995 (2006.01.01)
(19)CountryES
(41)Date of publication of the application2020.04.30
(49)Date of publication of the translation of the validated European patent specification2023.08.31
(30)Priority17382228, 2017.04.27, EP; 17382497, 2017.07.26, EP
(74)Patent attorney(Procedură) CORCODEL Angela, Bd. Ştefan cel Mare nr. 134, Chişinău, Republica Moldova
(86)International applicationPCT/EP2018/060868, 2018.04.27
(87)International publicationWO 2018/197663, 2018.11.01
Up
/Inventions/details/3615544